Torrent Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.
Torrent Pharmaceuticals Ltd., with Security Code 500420, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 27,450.00 | 4,490.00 | 27,760.00 | 13.27 | -6,970.00 | 310.00 | -2,030.00 | 6,310.00 |
| 2023-10-01 | 2023-12-31 | 21,230.00 | 2,970.00 | 21,120.00 | 8.78 | -4,980.00 | -110.00 | -1,910.00 | 4,300.00 |
| 2023-10-01 | 2023-12-31 | 27,320.00 | 4,430.00 | 26,990.00 | 13.10 | -6,700.00 | -330.00 | -2,130.00 | 6,310.00 |
| 2023-07-01 | 2023-09-30 | 21,460.00 | 3,270.00 | 21,610.00 | 9.65 | -5,190.00 | 150.00 | -1,920.00 | 4,820.00 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 14% |
| 3 Years: | 6% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 29% |
| 3 Years: | 24% |
| 1 Year: | 46% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 22% |
| 3 Years: | 9% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 29% |
| 3 Years: | 24% |
| 1 Year: | 46% |
Torrent Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for rabeprazole sodium tablets, a generic version of Nexium.
Torrent Pharmaceuticals reported a 32% increase in its net profit for the third quarter ended December 31, 2022, to Rs 934 crore.
Torrent Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to manufacture and market Molnupiravir, an oral antiviral drug for the treatment of mild to moderate COVID-19 in adults.
